MT Newswires Live2025-10-13
Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Group Weiqida Pharmaceutical, received approval from China's National Medical Products Administration for the marketing of active pharmaceutical ingredient sitagliptin phosphate, according to a Shanghai bourse filing on Saturday.
The Chinese pharmaceutical company's shares slipped over 1% at the close of Monday's trade.
The API is used clinically to improve blood glucose control in patients with type 2 diabetes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
